Orismilast in moderate-to-severe psoriasis: Efficacy and safety from a 16-week, randomized, double-blinded, placebo-controlled, dose-finding, and phase 2b trial (IASOS)

Richard B. Warren*, Lars E. French, Andrew Blauvelt, Richard G. Langley, Alexander Egeberg, Ulrich Mrowietz, Hamish J.A. Hunter, Melinda Gooderham, Per Soerensen, Philippe Andres, Morten O.A. Sommer, Anna Carlsson, Kim D. Kjøller, Bruce E. Strober

*Corresponding author for this work

Research output: Contribution to journal › Journal article › Research › peer-review

43 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Orismilast in moderate-to-severe psoriasis: Efficacy and safety from a 16-week, randomized, double-blinded, placebo-controlled, dose-finding, and phase 2b trial (IASOS)'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science